Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?
This article updates on two key legal cases in healthcare enforcement. First, in Regeneron, after the First Circuit ruled ...
The firm now models $4.35 billion in U.S. Eylea franchise revenues for 2026, well above the $3.86 billion consensus. BofA also highlighted upside from Dupixent, noting it “continues to deliver growth” ...
Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year. Few drugs become multi-billion blockbusters, but those that do ...
When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial. Now, the ...
Zacks Investment Research on MSN
REGN soars 41% in six months: Is there more upside potential in 2026?
The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR ...
Another attempt to take on Regeneron and Bayer's juggernaut Eylea is struggling in the clinic. This time, it’s Ribomic’s wet age-related macular degeneration (AMD) therapy RBM-007. The small biotech ...
The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...
Biosimilars are coming for Regeneron and Bayer’s Eylea’s crown, but the blockbuster reign is under no immediate threat of being overthrown. That’s according to a new joint analysis from analysts with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Eylea HD improved vision with extended dosing intervals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback